Currently, there are 256.14M common shares owned by the public and among those 247.13M shares have been available to trade.
However, the script later moved the day high at 9.74, down -3.31%. The company’s stock has a 5-day price change of -10.36% and 10.53% over the past three months. IOVA shares are trading 14.88% year to date (YTD), with the 12-month market performance up to 91.79% higher. It has a 12-month low price of $3.21 and touched a high of $18.33 over the same period. IOVA has an average intraday trading volume of 6.84 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.29%, -4.56%, and -9.83% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 68.15% of the company’s 256.14M shares outstanding.
It has a market capitalization of $2.83B and a beta (3y monthly) value of 0.63. The earnings-per-share (ttm) stands at -$1.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.40% over the week and 6.29% over the month.
Earnings per share for the fiscal year are expected to increase by 31.97%, and 44.22% over the next financial year.
Looking at the support for the IOVA, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on July 29, 2024, with the firm’s price target at $19-$10. Goldman coverage for the Iovance Biotherapeutics Inc (IOVA) stock in a research note released on November 20, 2023 offered a Buy rating with a price target of $12. Barclays was of a view on September 18, 2023 that the stock is Overweight, while Wells Fargo gave the stock Overweight rating on May 30, 2023, issuing a price target of $11- $17. Wells Fargo on their part issued Equal Weight rating on March 27, 2023.
